A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Summary

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.

Description

Eligibility

Age range

18+ years

Sex

Female

Healthy volunteers

No

Interventions

• Drug
  Atezolizumab - 28 Day Cycle

  Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.

• Drug
  Bevacizumab

  Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.

• Drug
  Ipatasertib

  Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.

• Drug
  Talazoparib

  Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.

• Drug
  Trastuzumab emtansine

  Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.

• Drug
  Tiragolumab

  Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.

Locations (21)